Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADVR:THE NEW COMPANY...WITH A NEW LIFE...AND A NEW MISSION -- Ignore unavailable to you. Want to Upgrade?

To: Kingfisher who wrote (4141)	7/27/1999 10:33:00 AM
From: paper man	Read Replies (2) \| Respond to of 4891

Kingfisher. Excellent points. I have declared before that the FDA has serious problems with the program they started about 3 years ago to bring drugs to market. because the FDA was lacking in foundational resources required to bring devloping drugs to market and suffering a run on serious complaints from drug companies about this lack of ability, THE FDA devloped a slush fund for those companies to contribute to to pay for the lacking services so they could speed the entry of new drugs. I think that last year big pharma poured 500 million + into this kitty of support. wondering how much AVR contributed? good luck

To: Kingfisher who wrote (4141)	7/30/1999 3:49:00 PM
From: BARRY ALLEN	Read Replies (2) \| Respond to of 4891

Tuesday, November 16, 1999 HIV HIV-1 Envelope Glycoproteins and Chemokine Receptors Interactions of Chemokine Receptors with CD4 and Their Role for HIV Entry Multiple Effects RANTES on Virus Replication Effects of Reticulose on the Expression of CCR5 Repression of CCR5 Gene with Engineered Transcription Factors 3:45 Effects of the Peptide Nucleic Acid Immunomodulator, Reticulose, on the Expression of CCR5 Chemokine Receptor and It's Coordinate Chemokines Dr. Shalom Z. Hirschman, President and CEO, Advanced Viral Research Corporation This presentation will deal with the effects of a new "switch-type" peptide nucleic acid immunomodulator on the synthesis of chemokines in various cell systems. The address will focus on the opposite effects of the immunomodulator on the synthesis of chemokines that are important in the cytocidal action of the immune system and the CCR5 chemokine receptor. Details of the activity of the immunomodulator in down-regulating the CCR5 chemokine receptor, and modulating the coordinate chemokines involved, will be discussed. healthtech.com